TEMCELL

Cynata approval for 1st ever allo trial of IPSC-derived MSCs for GVHD

Cynata

Cynata Therapeutics Limited has received approval from UK regulators to start a first-of-its-kind allogeneic IPSC-based trial of MSCs for graft versus host disease (GVHD).¬†Cynata also had some big news a couple weeks back with a deal with Fujifilm. The company is aiming to recruit 16 patients to test whether the MSCs (a type of adult …

Cynata approval for 1st ever allo trial of IPSC-derived MSCs for GVHD Read More »

Stem cell treatment cost 2.0: legit therapy

stem-money

We hear so much about exciting potential stem cell therapies, but what about stem cell treatment cost? Some of these “therapies” are rigorously evaluated ones in the FDA clinical trial pipeline and others are available right now mainly through predatory stem cell clinics. Earlier this year I posted about the cost of the offerings of …

Stem cell treatment cost 2.0: legit therapy Read More »